diagnosis and treatment of infertility, first/second/third generation IVF (including
egg/sperm donation), microsperm retrieval, embryo freezing and resuscitation, artificial
insemination (including husband's sperm and sperm donation), paternity testing, chromosomal
disease
diagnosis, high-throughput gene sequencing, endometrial receptivity gene testing and other
clinical
technology applications. Many of these technologies are at the leading level both domestically
and
internationally.
For many couples considering in vitro fertilization (IVF) treatment in Hong Kong, one of the first questions they ask is: How high are IVF success rates in Hong Kong?
Some hospitals report pregnancy rates exceeding 50%, while some patients find that they are unable to proceed with embryo transfer even after completing egg retrieval. Why do these seemingly contradictory outcomes occur?
The reason is that IVF is not a single procedure but a treatment process involving several medical stages. A high success rate at one stage does not necessarily mean that the entire treatment cycle will achieve the same outcome.
According to the 2025 Annual Statistics published by Hong Kong's Council on Human Reproductive Technology in September 2026, frozen-thawed embryo transfer treatments using the patient's and partner's own gametes or embryos recorded a clinical pregnancy rate of 42.7% per treatment cycle and an ongoing pregnancy rate of 36.2%.
These two figures represent different pregnancy outcomes and should not be interpreted as the final live birth rate.
It is important to note that the 2025 report remains an interim statistical release, and the corresponding live birth results will be included in a subsequent final report.
Therefore, describing the 42.7% figure as the "2026 IVF live birth rate in Hong Kong" would be a misinterpretation of the statistical indicator.
For patients preparing to undergo IVF treatment in Hong Kong, the first consideration should not simply be the embryo transfer success rate, but whether viable embryos suitable for transfer can be obtained.
Not all eggs retrieved after ovarian stimulation will be mature, and not all mature eggs will fertilize normally. Fertilized embryos must also undergo further laboratory culture and quality assessment.
For example, two women who are both 38 years old may receive similar ovarian stimulation protocols but ultimately obtain different numbers of usable embryos because of differences in ovarian reserve, egg quality, and sperm parameters.
This means that a hospital's published embryo transfer success rate does not fully reflect a patient's actual chances of progressing through treatment from the egg retrieval stage.
Women with low anti-Müllerian hormone (AMH) levels, a low antral follicle count (AFC), or a history of poor egg retrieval outcomes should pay particular attention to their expected ovarian response and the potential number of usable embryos, rather than focusing solely on embryo transfer statistics.
According to Hong Kong's official 2025 statistics on non-donor frozen-thawed embryo transfers, the ongoing pregnancy rate was 47.1% among women aged 31–35, 35.8% among those aged 36–40, and 21.4% among those aged 41–45.
These figures demonstrate differences in treatment outcomes across age groups, but they cannot be used to predict an individual patient's probability of success directly.
For frozen embryo transfers in particular, the woman's age at the time the embryos were created must also be considered.
For instance, a 42-year-old woman using embryos created and frozen several years earlier should not necessarily be assessed in the same way as a woman who begins egg retrieval at age 42.
As maternal age increases, the risk of chromosomal abnormalities in eggs generally rises. Meanwhile, AMH levels and antral follicle counts are primarily used to assess ovarian reserve and predict ovarian response to stimulation; neither can independently predict the final live birth outcome.
Therefore, older patients should focus on whether they still have a reasonable opportunity to obtain usable embryos and whether other reproductive health conditions need to be addressed simultaneously.
Obtaining usable embryos is only the prerequisite for entering the next stage of IVF treatment.
Following embryo transfer, several steps remain, including embryo implantation, confirmation of clinical pregnancy, ongoing pregnancy, and ultimately childbirth.
During this period, outcomes such as implantation failure, biochemical pregnancy, or pregnancy loss may occur.
This is why evaluating the clinical performance of an IVF hospital in Hong Kong should involve more than simply looking at positive pregnancy test results after embryo transfer.
For example, according to publicly available data from Hong Kong Union Hospital, the center reported an overall clinical pregnancy rate of 51% for fresh and frozen-thawed embryo transfers in 2025, while its corresponding published baby birth rate for 2024 was 40%.
Because these figures come from different reporting years and represent different pregnancy outcomes, they cannot be directly compared to calculate an individual's risk of pregnancy loss. However, they highlight an important distinction: the pregnancy rate and the baby birth rate are not the same statistical measure.
Rather than repeatedly searching for the hospital with the highest advertised IVF success rate, a more practical approach is to begin with a comprehensive assessment of your reproductive health.
Women can prepare recent hormone test results, AMH measurements, antral follicle ultrasound findings, and relevant uterine examination reports. Men should provide semen analysis results and other investigations as recommended by their physicians.
Couples with previous assisted reproductive treatment experience should also organize their past ovarian stimulation medication records, numbers of eggs retrieved, fertilization results, embryo culture records, and embryo transfer outcomes.
After receiving a proposed treatment plan from a hospital, three questions deserve particular attention:
First, how many usable embryos are expected to be obtained? Second, do the hospital's published statistics include cycles that did not reach embryo transfer? Third, what are the live birth outcomes among patients of similar ages and with comparable treatment conditions?
Hong Kong offers both public and private assisted reproductive healthcare services. However, patient demographics, treatment arrangements, and statistical reporting methods vary between institutions. Patients should verify the licensing status of their chosen clinic and make decisions based on their medical needs and actual treatment costs.
Yes, it is possible. Some patients achieve pregnancy and eventually have a live birth after their first embryo transfer, while others may require additional embryo transfers or another egg retrieval cycle.
Individual outcomes depend on factors such as embryo quality, age, and medical history. Success cannot be guaranteed in advance.
Not necessarily. Preimplantation genetic testing (PGT) is primarily used when specific medical indications are present.
It does not mean that using this technology will improve the cumulative chance of live birth per egg retrieval cycle for every patient.
A reproductive medicine assessment may still be appropriate. However, whether to begin treatment should depend on ovarian reserve, previous treatment history, overall health, and the physician's assessment of likely outcomes.
Traveling to Hong Kong for IVF does not change the biological limitations associated with reproductive aging.
IVF success rates in Hong Kong cannot be represented by a single fixed percentage that applies to every patient or family.
From egg retrieval and embryo development to embryo transfer, ongoing pregnancy, and eventual childbirth, each stage influences the final outcome.
For patients considering IVF treatment in Hong Kong, the most meaningful figures are not the highest success rates highlighted in promotional materials, but statistics that reflect their own age, embryo characteristics, and the complete treatment process.
Sources: 2025 Annual Statistics, Council on Human Reproductive Technology, Hong Kong; publicly available information from the Reproductive Medicine Centre of Hong Kong Union Hospital.
This article is intended for medical information purposes only. Specific treatment plans should be developed by licensed healthcare institutions according to each patient's individual circumstances.
🏥 Located in downtown Bishkek, the capital of Kyrgyzstan, near the National Museum and Victory Square. It is the first Chinese-invested, officially licensed assisted reproductive hospital in the country. Founded and directly operated by Mr. Chen Yinuo (EnoChan), the center specializes in high-level fertility services including PGT (3rd generation IVF) and legal third-party reproduction for global clients, especially Chinese patients.
🌷 Technology-Assisted Fertility, Fulfilling Dreams · Patience · Integrity · Professionalism

